Global Migraine Drugs Market By Overview
Introduction:
A migraine may be a medical condition which usually causes a pounding, throbbing headache on one side of the top. The pain could also be very bad and hurt such a lot that an individual may have a tough time doing anything. While most of the people who have migraines get a headache, not everyone does. There are different sorts of migraines, and a few don't cause a headache but do produce other symptoms. Most migraines cause a headache and nausea and might make the person dizzy or very sensitive to bright lights or loud noises. Some people have "auras" before a migraine starts, which suggests their ability to ascertain becomes different. They see funny patterns, have blurry vision, or might not be ready to see in the least. Other senses can change before or during a migraine, and therefore the person may sense funny smells or tastes. Migraines can last an extended time. Migraines usually last between four and 72 hours. Migraine is a neurological condition in which recurring type of headache cause moderate to severe pain that is throbbing or pulsing.The Migraine Drugs Market accounted for US$ 2.2 billion in 2020 and is estimated to be US$ 8.3 billion by 2030 and is anticipated to register a CAGR of 15.70%
Global Migraine Drugs Market By Dynamics
Increasing incidences of migraine attack
Increasing incidences of migraine attack across the globe is major factor driving the migraine drugs market. For instance, according to data published For instance, according to data published by National Centre of Biotechnology Information, in June 2018, migraine prevalence is reported as between 2.6% and 21.7%, with an average of ~12% across the globe. In addition, rising demand for anti-migraine drugs to prevent the attacks or relieve the symptoms during the attack is propelling the target market. For instance, according to data published by National Centre of Biotechnology Information, in 2018, erenumab is first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine in adults.
Unhealthy lifestyle of individuals
Furthermore, unhealthy lifestyle of individuals, stress and anxiety, skipped meals, bright light, and loud noises are responsible for migraine is expected to fuel the migraine drugs market over the forecast period. Moreover, increasing uptake of novel drug classes, high unmet needs, and launch of calcitonin gene-related peptide (CGRP)-based therapies are another factors boosting the migraine drugs market. Growing focus on drug development is expected to augment the target market in the near future.
However, side effects are occurred due to migraine drugs may restrain the migraine drugs market.
Global Migraine Drugs Market By Segmentation
The migraine drugs market report segments the market on the basis of treatment, route of administration, distribution channel, and region.
On the basis of treatment, the target market is segmented into abortive or acute and prophylactic or preventive. Abortive or acute sub-segment is categorized into triptans, ergot alkaloids, and anti-nausea medications. Further, prophylactic or preventive sub-segment is bifurcated into botulinum toxin, topiramate, and glucocorticoids. On the basis of route of administration, the migraine drugs market is classified into oral, injectable, and others. Others route of administration sub-segment is nasal spray and transdermal patch. On the basis of distribution channel, the target market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies.
Regional Insights:
For detailed understanding of market dynamics, the migraine drugs market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the migraine drugs market. In 2018, the North America migraine drugs market is expected to account for major revenue share in migraine drugs market, followed by other regions. This is attributed to rising penetration of migraine in the countries of the North America region. For instance, according to data published by National Institutes of Health (NIH), in 2017, 12% of Americans (about 37 million people) have migraines. These debilitating headaches affect children and adults, and women are three times more likely to have migraines than men (about 18 % of women have migraines). Asia Pacific migraine drugs market is emerging market in the global migraine drugs market. This is owing to increasing expenditure on healthcare, a large underserved patient population, low-cost production of drugs, and growing disease awareness in countries of the region.
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Treatment: Abortive or Acute and Prophylactic or Preventive By Route of Administration: Oral, Injectable, and Others (Nasal Spray and Transdermal Patch) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Detailed Segmentation:
Migraine Drugs Market, By Treatment:
- Abortive or Acute
- Prophylactic or Preventive
Migraine Drugs Market, By Route of Administration:
- Oral
- Others
- Injectables
Migraine Drugs Market, By Distribution Channel:
- Retail pharmacies
- Retail Pharmacies
- Hospital Pharmacies
Migraine Drugs Market, By Region:
- North America
- Africa
- Africa Migraine Drugs Market, By Treatment
- Africa Migraine Drugs Market, By Route of Administration
- Africa Migraine Drugs Market, By Distribution Channel
- Africa Migraine Drugs Market, By Country
- North Africa
- Central Africa
- South Africa
- Middle East
- Middle East Migraine Drugs Market, By Treatment
- Middle East Migraine Drugs Market, By Route of Administration
- Middle East Migraine Drugs Market, By Distribution Channel
- Middle East Migraine Drugs Market, By Country
- GCC
- Israel
- Rest of Middle East
- Latin America
- Latin America Migraine Drugs Market, By Treatment
- Latin America Migraine Drugs Market, By Route of Administration
- Latin America Migraine Drugs Market, By Distribution Channel
- Latin America Migraine Drugs Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Asia-Pacific
- Asia-Pacific Migraine Drugs Market, By Treatment
- Asia-Pacific Migraine Drugs Market, By Route of Administration
- Asia-Pacific Migraine Drugs Market, By Distribution Channel
- Asia-Pacific Migraine Drugs Market, By Country
- China
- India
- Australia
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Europe Migraine Drugs Market, By Treatment
- Europe Migraine Drugs Market, By Route of Administration
- Europe Migraine Drugs Market, By Distribution Channel
- Europe Migraine Drugs Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Migraine Drugs Market, By Treatment
- North America Migraine Drugs Market, By Route of Administration
- North America Migraine Drugs Market, By Distribution Channel
- North America Migraine Drugs Market, By Country
- U.S.
- Canada
- Africa
Global Migraine Drugs Market By Key Players
Some of the prominent players operating in the migraine drugs market include Pfizer Inc, GlaxoSmithKline plc, Allergan plc, Amgen Inc, Eli Lilly and Company, Teva Pharmaceuticals USA, Inc, Biohaven Pharmaceutical Holding Company Ltd, Johnson & Johnson, Novartis Pharmaceuticals Canada Inc., and Alembic Pharmaceuticals Limited. Technological advancements in the product as well as in manufacturing process, product launches, and strategic partnerships are some trends witnessed in the migraine drugs market. For instance, in September 2018, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) have approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Further, on August 2018, Novartis Pharmaceuticals Canada Inc announced that Health Canada has approved Aimovig (erenumab) for the prevention of migraine in adults who have at least four migraine days per month.
Global Migraine Drugs Market By Company Profile
- Cargill Incorporated
- Alembic Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Novartis Pharmaceuticals Canada Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Biohaven Pharmaceutical Holding Company Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Teva Pharmaceuticals USA, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Amgen Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Allergan plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Pfizer Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Alembic Pharmaceuticals Limited
Global Migraine Drugs Market By Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Product Launch
- Pipeline Analysis
- Recent Approvals
- Impact Analysis
- PEST Analysis
- Porter’s Analysis
- Market Dynamics
- Market Segmentation, By Treatment, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Abortive or Acute
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Triptans
- Ergot Alkaloids
- Anti-Nausea Medications
- Prophylactic or Preventive
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Botulinum Toxin
- Topiramate
- Glucocorticoids
- Overview
- Market Segmentation, By Route of Administration, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Oral
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Injectable
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Others (Nasal Spray and Transdermal Patch)
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By Distribution Channel, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Retail Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Hospital Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Online Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2019 — 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Treatment, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Route of Administration, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2019 – 2029
- Market Size and Forecast (US$ Bn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Overview
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Pfizer Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Allergan plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Amgen Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Teva Pharmaceuticals USA, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Biohaven Pharmaceutical Holding Company Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Alembic Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Pfizer Inc
- Analyst Views
- Section
- Research Methodology
- About Us
- Contact
FAQs
The migraine drugs market report segments the market on the basis of treatment, route of administration, distribution channel, and region.
Increasing incidences of migraine attack across the globe is major factor driving the migraine drugs market.
North America migraine drugs market is expected to account for major revenue share in migraine drugs market, followed by other regions.
Some of the prominent players operating in the migraine drugs market include Pfizer Inc, GlaxoSmithKline plc, Allergan plc, Amgen Inc, Eli Lilly and Company, Teva Pharmaceuticals USA, Inc, Biohaven Pharmaceutical Holding Company Ltd, Johnson & Johnson, Novartis Pharmaceuticals Canada Inc., and Alembic Pharmaceuticals Limited.